Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Genomic Analysis of Families With a History of Discordant Cancers

NCT04860453 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to identify novel gene mutations which have contributed to significant personal and family history of cancer. Adults with and without cancer will be accrued to the study. Participants qualify to take part in this research study because someone in their family has been diagnosed with or because they themselves have a cancer diagnosis. Participants' DNA and other clinical information will be obtained from a blood sample in order to study the genetic basis of cancer and related complications. All portions in the DNA that code for proteins (i.e., the exome) will be studied. Participant DNA sample and information about family structure and family medical history and ethnic origin may also be collected to better understand this information. Clinical information will be stored and biological samples, including DNA, will be kept for up to three (3) years after collection for future. Ultimately, once identified, the role of the specific genetics changes in the development of inherited cancer(s) will be characterized.

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST Blood Draw
  • GENETIC WES via Illumina NextSeq 550 sequencing system
  • DIAGNOSTIC_TEST Skin biopsy
  • DIAGNOSTIC_TEST Saliva Sample

Study Locations (1)

Ohio

  • University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center — Cleveland

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2020-11-17
Est. Completion 2028-07-01

Sponsor

Case Comprehensive Cancer Center

276 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04860453

The ClinicalTrials.gov registry entry for NCT04860453 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 276 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Discordant Cancers appearing as the primary indexed condition, and to 4 interventions — of which Blood Draw is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04860453 reports 1 study location spanning 1 distinct geographic area — top geographies include Ohio. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04860453 about?

NCT04860453 is a clinical study titled "Genomic Analysis of Families With a History of Discordant Cancers". The purpose of this study is to identify novel gene mutations which have contributed to significant personal and family history of cancer. Adults with and without cancer will be accrued to the study. Participants qualify to take part in this research study because someone in their family has been di...

What is the current status of trial NCT04860453?

This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2020-11-17. Estimated completion is 2028-07-01.

What conditions does trial NCT04860453 study?

This clinical trial studies the following conditions: Discordant Cancers. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04860453?

The interventions under investigation include: Blood Draw (DIAGNOSTIC_TEST), WES via Illumina NextSeq 550 sequencing system (GENETIC), Skin biopsy (DIAGNOSTIC_TEST), Saliva Sample (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04860453?

This trial is sponsored by Case Comprehensive Cancer Center, which has 276 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04860453 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial